MCTD manifestation | MCTD (n = 50) | MCTD/CVD+ (n = 23) | MCTD/CVD- (n = 27) | Pvaluea, CVD+ vs. CVD- |
---|---|---|---|---|
Disease duration (years) | 9.56 ± 6.8 (3 to 26) | 10.3 ± 6.6 (3 to 26) | 8.9 ± 6.9 (3 to 25) | 0.481 |
Polyarthritis | 46 (92) | 22 (95.6) | 24 (88.8) | 0.6123 |
Raynaud's phenomenon | 39 (78) | 22 (95.6) | 17 (62.9) | 0.006 |
Myositis | 30 (60) | 13 (56.5) | 17 (62.9) | 0.8621 |
Interstitial lung disease | 40 (80) | 19 (82.6) | 21 (77.7) | 0.7356 |
Photosensitivity | 12 (24) | 7 (30.4) | 5 (18.5) | 0.5077 |
Esophageal dysmotility | 35 (70) | 15 (65.2) | 20 (74.0) | 0.5480 |
Pulmonary arterial hypertension | 12 (24) | 9 (39.1) | 3 (11.1) | 0.0141 |
Lymphadenomegaly | 13 (0.26) | 5 (21.7) | 8 (29.6) | 0.7474 |
Serositis | 19 (38) | 11 (47.8) | 8 (29.6) | 0.2465 |
Secondary antiphospholipid syndrome | 15 (30) | 11 (47.8) | 4 (14.8) | 0.015 |
Previous venous thrombosis | 13 (26.0) | 9 (39.1) | 4 (14.8) | 0.618 |
Previous arterial occlusion | 2 (4.0) | 2 (8.69) | 0 | Â |
Anti-U1RNP (normal: <10 U/ml) | 50 (100) | 23 (100) | 27 (100) | Â |
Anti-CL IgG/IgM (normal: <10 U/ml) | 19 (38) | 13 (56) | 6 (22) | 0.0195 |
AECA (normal: <5 U/ml) | 22 (44) | 15 (65) | 7 (26) | 0.001 |
SLAM (median) | 5 | 5 | 4 | Â |
SLAM (mean ± SD) | 6.28 ± 4.04 | 6.95 ± 4.08 | 5.44 ± 4.0 | 0.199 |
SLAM (n) | 18 (36) | 11 (47.8) | 7 (25.9) | 0.1438 |
Medication | Â | Â | Â | Â |
   Nonsteroidal anti-inflammatory drugs | 22 (44) | 10 (43.4) | 12 (44.4) | 1.0 |
Last 2 months average dose of corticosteroids (mg/day) | 3.36 ± 4.8 | 4.1 ± 3.4 | 3.1 ± 5.2 | 0.5306 |
Cumulative lifetime dose (prednisone equivalent) | 14.21 (4 to 58.965) | 13.0 (4 to 59.432) | 15.2 (4 to 57.437) | 0.674 |
Corticosteroids alone or combination (n) | 28 (56) | 11 (47.8) | 17 (62.9) | 0.3926 |
Patients currently corticosteroids alone n (%) | 7 (14) | 2 (8.6) | 5 (18.5) | 0.4295 |
Patients currently corticosteroids plus salazopyrine | 10 (20) | 5 (21.7) | 5 (18.5) | 1.0 |
Patients currently corticosteroids plus methotrexate | 11 (22) | 5 (21.7) | 6 (22.2) | 1.00 |
   Cyclophosphamide treatment ever | 37 (74) | 21 (91.3) | 16 (59.2) | 0.0119 |
   Antimalaric drugs treatment ever | 39 (78) | 19 (82.6) | 20 (74.0) | 0.515 |
   Cyclosporin-A treatment ever | 10 (20) | 7 (30.4) | 3 (11.1) | 0.4804 |